SCHEMBL2965452

SCHEMBL2965452

CNN(C(=O)O)C(CC=O)C1CCN(CCc2cc(-c3ccc(Cl)cc3)on2)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.37
RAB9A P51151 4/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
DRD4 P21917 3/20 0.37
DRD3 P35462 3/20 0.37
DRD2 P14416 2/20 0.37
MAPT P10636 4/20 0.37
POLB P06746 3/20 0.37
NOTUM Q6P988 1/20 0.37
CYP1A2 P05177 4/20 0.37
CYP2D6 P10635 3/20 0.37
CYP2C9 P11712 2/20 0.37
CYP2C19 P33261 2/20 0.37
GAA P10253 1/20 0.37
F10 P00742 1/20 0.37
CYP3A4 P08684 2/20 0.35
TSHR P16473 2/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
ALDH1A1 P00352 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2981437 0.95 MAPT (0.39) NPC1RAB9ASMN1; SMN2DRD4DRD3
SCHEMBL2981410 0.86 LMNA (0.40) SMN1; SMN2DRD4DRD3DRD2MAPT
SCHEMBL2976754 0.83 LMNA (0.39) SMN1; SMN2DRD4DRD3DRD2POLB
SCHEMBL2975031 0.82 ARG1 (0.43) MAPTF10
SCHEMBL2972024 0.81 DRD2 (0.42) NPC1RAB9ASMN1; SMN2DRD4DRD3
SCHEMBL2967614 0.79 NOTUM (0.38) NPC1RAB9ASMN1; SMN2MAPTNOTUM
SCHEMBL2970171 0.78 TEAD1 (0.45) MEN1KMT2A
SCHEMBL2979868 0.78 OPRM1 (0.43)
Hydrochloric Acid SCHEMBL2971262 0.78 TEAD1 (0.44) MEN1KMT2A
SCHEMBL2983978 0.77 MEN1 (0.51) DRD3DRD2MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7781590-B2 Piperidinylalkylcarbamate derivatives, methods for their preparation and the therapeutic use thereof as fatty acid amido hydrolase enzyme inhibitors SANOFI-AVENTIS (FR) 2010-08-24 US disclosed
US-20070021403-A1 PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS SANOFI-AVENTIS (FR) 2007-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021403-A1 PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS FAAH, FAAH2, CNR2 NPC1 558/4885RAB9A 2075/4885SMN1; SMN2 4631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.